92 -10 (72) 2024 - Khakimov G.A. Khakimova G.G. - CLINICAL CASE: NEUROENDOCRINE PROSTATE CANCER.

CLINICAL CASE: NEUROENDOCRINE PROSTATE CANCER.

Khakimov G.A. - Tashkent Pediatric Medical Institute, Tashkent city branch of the Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology

Khakimova G.G. - Tashkent Pediatric Medical Institute, Tashkent city branch of the Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology

Qodirov Sh.Sh. - Tashkent Pediatric Medical Institute, Tashkent city branch of the Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology

Resume

Neuroendocrine prostate cancer is a rare and aggressive cancer with a poor prognosis. This type of cancer is often diagnosed at an advanced stage and exhibits rapid resistance to standard therapeutic methods. Taking into account the low occurrence of this phenomenon, a description of poorly differentiated neuroendocrine (small cell) prostate cancer with extremely aggressive forms is given.

Keywords: neuroendocrine cancer, castration-resistant cancer, prostate, hormone resistance

First page

510

Last page

515

For citation:Khakimov G.A. Khakimova G.G. Qodirov Sh.Sh. - CLINICAL CASE: NEUROENDOCRINE PROSTATE CANCER.//New Day in Medicine 10(72)2024 510-515 https://newdayworldmedicine.com/en/new_day_medicine/10-72-2024

List of References

  1. Aggarwal R, Zhang T, Small EJ, Armstrong AJ. Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. J Natl Compr Canc Netw 2014;12(5):719-26. DOI: 10.6004/jnccn.2014.0073
  2. Hirano D, Okada Y, Minei S. et al. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 2004;45(5):586–92. DOI: 10.1016/j.eururo.2003.11.032
  3. Aggarwal R., Huang J., Alumkal J.J. et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J Clin Oncol 2018;36(24):2492–503. DOI: 10.1200/JCO.2017.77.6880
  4. Abida W, Cyrta J, Heller G. et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci USA 2019;116(23):11428-36. DOI: 10.1073/pnas.1902651116
  5. Bluemn E.G., Coleman I.M., Lucas J.M. et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF sig- naling. Cancer Cell 2017;32(4):474-89. DOI: 10.1016/j.ccell.2017.09.003
  6. Beltran H., Prandi D., Mosquera J.M. et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med 2016;22(3):298–305. DOI: 10.1038/nm.4045
  7. Zhang Y., Zheng D., Zhou T. et al. Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB- EZH2-TSP1 pathway in prostate cancers. Nat Commun 2018;9(1):4080. DOI: 10.1038/s41467-018-06177-2
  8. Puca L., Vlachostergios P.J., Beltran H. Neuroendocrine differentiation in prostate cancer: emerging biology, models, and therapies. Cold Spring Harb Perspect Med 2019;9(2):30593. DOI: 10.1101/cshperspect.a030593
  9. Montironi R., Cimadamore A., Lopez-Beltran A. et al. Morphologic, molecular and clinical features of aggressive variant prostate cancer. Cells 2020;9(5):1073. DOI: 10.3390/cells9051073
  10. Mahal B.A., Yang D.D., Wang N.Q. et al. Clinical and genomic characterization of low-prostate-specific antigen, high-grade prostate can- cer. Eur Urol 2018;74(2):146–54. DOI: 10.1016/j.eururo.2018.01.043
  11. Wang J., Xu W., Mierxiati A. et al. Low-serum prostate-specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer. Prostate 2019;79(13):1563–71. DOI: 10.1002/pros.23878
  12. Helpap B, Köllermann J, Oehler U. Neuroendocrine differentiation in prostatic carcinomas: histogenesis, biology, clinical relevance, and future therapeutical perspectives. Urol Int. 1999;62(3):133-8.
  13. Stenman UH, Abrahamsson PA, Aus G, Lilja H, Bangma C, Hamdy FC, et al. Prognostic value of serum markers for prostate cancer. Scand J Urol Nephrol Suppl. 2005(216):64-81.
  14. Nadal R, Schweizer M, Kryvenko ON, Epstein JI, Eisenberger MA. Small cell carcinoma of the prostate. Nat Rev Urol. 2014;11(4):213-9.
  15. Conteduca V, Oromendia C, Eng KW, Bareja R, Sigouros M, Molina A, et al. Clinical features of neuroendocrine prostate cancer. Eur J Cancer. 2019;121:7-18.
  16. Apostolidis L., Nientiedt C., Winkler E.C. et al. Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate. Oncotarget 2019;10(1):17–29. DOI: 10.18632/oncotarget.26523
  17. Zhu J., Liang X., Wu D. et al. Clinicopathological characteristics and survival outcomes in neuroendocrine prostate cancer: a population-based study. Medicine (Baltimore) 2021;100(15):25237. DOI: 10.1097/MD.0000000000025237
  18. Vlachostergios P.J., Papandreou C.N. Targeting neuroendocrine prostate cancer: molecular and clinical perspectives. Front Oncol 2015;5:6. DOI: 10.3389/fonc.2015.00006
  19. Papandreou C.N., Daliani D.D., Thall P.F. et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 2002;20(14):3072–80. DOI: 10.1200/JCO.2002.12.065
  20. Culine S., El Demery M., Lamy P.J. et al. Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J Urol 2007;178:844–8. DOI: 10.1016/j.juro.2007.05.044

    file

    download